Celcuity

Celcuity Retained Earnings

The Retained Earnings of Celcuity (CELC) as of Nov 11, 2026 is -448.90 M USD. In the previous year, Retained Earnings was -271.86 M USD — a change of 65.12% (lower).

Retained Earnings

-448.90 MUSD

YoY

65.12%

Last updated:

Retained Earnings of Celcuity is 2025 -448.90 M USD. Retained Earnings of Celcuity was 2024 -271.86 M USD. It decreases by 65.12% lower compared to the previous year.

The Celcuity Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
-9.49 M USD
Jan 1, 2019
-16.85 M USD
Jan 1, 2020
-26.32 M USD
Jan 1, 2021
-55.93 M USD
Jan 1, 2022
-96.30 M USD
Jan 1, 2023
-160.08 M USD
Jan 1, 2024
-271.86 M USD
Jan 1, 2025
-448.90 M USD
The Celcuity Retained Earnings history
YEARRetained EarningsYoY
-448.90 MUSD+65.12%
-271.86 MUSD+69.83%
-160.08 MUSD+66.23%
-96.30 MUSD+72.18%
-55.93 MUSD+112.48%
-26.32 MUSD+56.24%
-16.85 MUSD+77.56%
-9.49 MUSD+372.69%
-2.01 MUSD-75.91%
-8.33 MUSD+65.93%
-5.02 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Retained Earnings of Celcuity is -448.90 M USD in 2025.

Retained Earnings of Celcuity changed from -271.86 M USD to -448.90 M USD, representing a 65.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Celcuity since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Celcuity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Celcuity

All Key Metrics — Celcuity